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Slovenia’s estimated 1%–2.5% hepatitis C virus (HCV)
seroprevalence rate in the general population is much
lower than the 3.5% rate reported by neighbouring Italy
[1]. There are an estimated 10,000 people who inject
drugs (PWID) in Slovenia, a country of two million. HCV
seroprevalence in PWID in Slovenia has been estimated at
23% – the second-lowest rate in the European region –
and HIV co-infection is extremely rare [2,3]. Around
4,500 PWID per year receive services at regional Centers
for the Prevention and Treatment of Drug Addiction
(CPTDA), with around three-quarters receiving opioid
substitution treatment [4]. In 2006, HCV RNA prevalence
among 1,450 PWID managed at CPTDA was 15.6%; 1% of
the infected cohort had completed HCV treatment and 3%
were currently receiving it [5].
In Slovenia, the relatively low HCV seroprevalence in
PWID most probably reflects the systematic introduction
of various well-established harm reduction interventions
in the early 1990s [4]. At the beginning of the last decade,
however, the HCV treatment rate for PWID was reported
to be very low, as was the case in other European
countries [6]. To increase the HCV treatment rate, a
national model for the management of HCV infection in
this vulnerable population was introduced.
HCV is managed by two institutions in Slovenia: the
National Institute of Public Health of the Republic of Slo-
venia and the National Viral Hepatitis Expert Group, the
latter a multidisciplinary body of experts from various
public medical institutions. The National Institute of
Public Health is responsible for national epidemiological
surveillance and for HCV prevention strategies such as
blood safety, vaccination and contact tracing. The National
Viral Hepatitis Expert Group, which was founded by a
self-initiative in 1997, guides the overall national strategy
for the management of viral hepatitis, drawing on best
practices and standards of care as much as possible. Case
finding in special groups, anonymous testing, treatment,
national consensus guidelines, research, education and
mass media campaigns are all issues that fall within the
Expert Group’s domain [7].
Slovenia formulated national guidelines for treatment of
HCV infection in 1997, basing the guidelines on interna-
tional recommendations while taking into account
national particularities [7]. Treatment in Slovenia is fully
publicly funded and is provided with no limitations except
for one: it must be prescribed by viral hepatitis specialists
at one of five hospital-based clinics in accordance with
national guidelines. The 1997 guidelines did not exclude
PWID from HCV treatment, stating that treatment
decisions should be made on an individual basis. Since
1997, the Expert Group has systematically monitored
treatment efficacy and safety in Slovenian patients treated
for hepatitis C.
In 1995, 18 CPTDA were established in Slovenia. When
a PWID enters a CPTDA programme, the person is
offered HCV testing. Individuals who test negative are
invited to be tested again every six to 12 months [4]. To
increase the proportion of PWID treated for HCV and to
achieve optimal treatment adherence, efficacy and safety, a
multidisciplinary national healthcare network for the
treatment of HCV infection in PWID was established in
2007 [8]. This network linked the 18 CPTDA and the five
specialised hosptial-based clinics for treatment of viral
hepatitis. The Clinic for Infectious Diseases and Febrile
Illnesses at the University Medical Centre in Ljubljana
serves as the reference institution.
The network for the treatment of HCV in PWID
includes clinical care providers (addiction therapists and
viral hepatitis specialists, most of whom are infectologists),
counsellors (nurses and social workers), and psychiatrists
who have acquired additional medical education and sup-
portive training. It also includes peers and other members
of patient support systems such as family members,
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friends and co-workers. Collaboration among all involved
health professionals takes place through participation in
national conferences that have been held annually since
2006.
Slovenian national consensus guidelines for the manage-
ment of HCV infection in drug users were established in
2007 [8]. These guidelines set forth best practices for the
comprehensive management of HCV-infected PWID.
They provide best practices for screening and identifying
treatment-eligible PWID, as well as for providing them
with high-quality HCV education, counselling and motiva-
tion. Best practices for treatment of HCV in clinical
settings for viral hepatitis are provided, with at least
monthly interventions performed individually throughout
the treatment period in close cooperation between viral
hepatitis specialists and addiction therapists.
Before the introduction of the multidisciplinary model,
PWID made up the following proportions of all patients
treated for HCV in Slovenia: 5% in 1997–1999, 16% in
1999–2001 and 36% in 2002–2004 [9-11]. In 2008–2010,
this proportion increased to 78%. It is notable that by the
end of 2010 approximately 13% of HCV-infected PWID
at CPTDA had already received treatment. The sustained
virological response among PWID was 80% in the last
monitoring period [11].
In conclusion, the multidisciplinary healthcare network
enables individual evaluation and management of
HCV-infected PWID by both drug addiction therapists
and viral hepatitis specialists in a convenient, experienced
and effective manner in the context of Slovenian circum-
stances. Since healthcare systems and settings vary greatly
across Europe, each European country should try to
develop its own interdisciplinary model for addressing the
treatment of HCV in PWID.
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